1 active not recruiting, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Alterome Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations ALTA3263, cetuximab, mFOLFOX6 - Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Alterome Therapeutics, Inc. | 448 | 2025-03-05 | 2026-06-10 |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors ALTA2618 - Cancer, Breast Cancer | Phase 1 | Active not recruiting | Alterome Therapeutics, Inc. | 110 | 2024-08-22 | 2026-07-15 |
Neoplasm Metastasis (2) · Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Genital Neoplasms, Female (1) · Lung Neoplasms (1) · Neoplasms by Site (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Midazolam (1) · Pemetrexed (1) · pembrolizumab (1)
United States (2) · Australia (1) · France (1) · Japan (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)